LUYE PHARMA GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.72 HKD | +0.74% |
|
+4.21% | -27.08% |
| Sales 2023 | 6.14B 848M 6.64B 67.89B | Sales 2024 * | 6.79B 937M 7.33B 75.03B | Capitalization | 9.47B 1.31B 10.23B 105B |
|---|---|---|---|---|---|
| Net income 2023 | 533M 73.56M 576M 5.89B | Net income 2024 * | 658M 90.81M 711M 7.27B | EV / Sales 2023 | 2.08 x |
| Net Debt 2023 * | 3.67B 506M 3.96B 40.55B | Net Debt 2024 * | 2.95B 407M 3.18B 32.57B | EV / Sales 2024 * | 1.83 x |
| P/E ratio 2023 |
23.7
x | P/E ratio 2024 * |
15.6
x | Employees | 5,005 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 54.94% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.74% | ||
| 1 week | +4.21% | ||
| Current month | -0.37% | ||
| 1 month | -4.23% | ||
| 3 months | -7.17% | ||
| 6 months | -21.39% | ||
| Current year | -27.08% |
1 week
2.59
2.77
1 month
2.552.95
Current year
2.343.77
1 year
2.344.03
3 years
1.885.84
5 years
1.887.48
10 years
1.8811.54
| Managers | Title | Age | Since |
|---|---|---|---|
Dian Bo Liu
CEO | Chief Executive Officer | 59 | 01/07/03 |
Rong Bing Yang
PSD | President | 58 | 07/06/94 |
Yun Li Xue
PRN | Corporate Officer/Principal | 60 | 07/06/94 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Xian Yuan
BRD | Director/Board Member | 65 | 07/06/94 |
Rong Bing Yang
PSD | President | 58 | 07/06/94 |
Dian Bo Liu
CEO | Chief Executive Officer | 59 | 01/07/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.58% | 4 M€ | -27.92% | ||
| 0.15% | 2 M€ | -14.14% | ||
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.72 | +0.74% | 25,125,600 |
| 25/04/24 | 2.7 | +0.37% | 24,784,800 |
| 24/04/24 | 2.69 | +1.51% | 8,040,500 |
| 23/04/24 | 2.65 | -0.38% | 7,601,500 |
| 22/04/24 | 2.66 | +1.92% | 23,062,500 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Companyâs main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimerâs disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.518
CNY
Average target price
2.785
CNY
Spread / Average Target
+10.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.08% | 1.31B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 2186 Stock
